Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Preparation and testing of a Vi conjugate vaccine using pneumococcal surface protein A (PspA) from Streptococcus pneumoniae as the carrier protein.
[typhoid]
In
the
current
study
pneumococcal
surface
protein
A
(
PspA
)
was
conjugated
to
Vi
capsular
polysaccharide
from
Salmonella
Typhi
to
make
available
a
vaccine
against
typhoid
fever
that
has
the
potential
to
also
provide
broad
protection
from
Streptococcus
pneumoniae
.
High
yielding
production
processes
were
developed
for
the
purification
of
PspAs
from
families
1
and
2
.
The
purified
PspAs
were
conjugated
to
Vi
with
high
recovery
of
both
Vi
and
PspA
.
The
processes
developed
especially
for
PspA
family
2
could
readily
be
adapted
for
large
scale
production
under
cGMP
conditions
.
Previously
we
have
shown
that
conjugation
of
diphtheria
toxoid
(
DT
)
to
Vi
polysaccharide
improves
the
immune
response
to
Vi
but
can
also
enhance
the
response
to
DT
.
In
this
study
it
was
shown
that
conjugation
of
PspA
to
Vi
enhanced
the
anti-
PspA
response
and
that
PspA
was
a
suitable
carrier
protein
as
demonstrated
by
the
characteristics
of
a
T
-
cell
dependent
response
to
the
Vi
.
We
propose
that
a
bivalent
vaccine
consisting
of
PspA
from
families
1
and
2
bound
to
Vi
polysaccharide
would
protect
against
typhoid
fever
and
has
the
potential
to
also
protect
against
pneumococcal
disease
and
should
be
considered
for
use
in
developing
countries
.
Diseases
Validation
Diseases presenting
"has the potential to also protect against pneumococcal disease and should be considered for use in developing countries"
symptom
typhoid
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom